 Shikha Sundaram
Concepts (217)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 25 | 2025 | 827 | 4.470 |
Why?
| | Biliary Atresia | 9 | 2024 | 158 | 2.720 |
Why?
| | Fatty Liver | 5 | 2026 | 253 | 2.130 |
Why?
| | Sarcopenia | 4 | 2023 | 91 | 2.120 |
Why?
| | Non-alcoholic Fatty Liver Disease | 10 | 2024 | 265 | 2.050 |
Why?
| | Liver Diseases | 3 | 2025 | 305 | 1.660 |
Why?
| | Pediatric Obesity | 3 | 2026 | 638 | 1.200 |
Why?
| | Cholestasis | 4 | 2025 | 214 | 1.130 |
Why?
| | End Stage Liver Disease | 2 | 2021 | 95 | 1.060 |
Why?
| | Muscle, Skeletal | 2 | 2026 | 1791 | 0.890 |
Why?
| | Human Growth Hormone | 1 | 2025 | 47 | 0.880 |
Why?
| | Muscular Atrophy | 1 | 2025 | 87 | 0.860 |
Why?
| | Child | 37 | 2025 | 22740 | 0.790 |
Why?
| | Bariatric Surgery | 2 | 2025 | 253 | 0.730 |
Why?
| | Sleep Apnea, Obstructive | 2 | 2018 | 303 | 0.690 |
Why?
| | Obesity, Morbid | 1 | 2025 | 293 | 0.680 |
Why?
| | Hepatoblastoma | 1 | 2022 | 52 | 0.670 |
Why?
| | Hepatopulmonary Syndrome | 2 | 2021 | 23 | 0.660 |
Why?
| | Malnutrition | 1 | 2021 | 86 | 0.640 |
Why?
| | Hypoxia | 3 | 2018 | 1199 | 0.620 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2022 | 373 | 0.560 |
Why?
| | Liver | 8 | 2025 | 1899 | 0.520 |
Why?
| | Liver Failure, Acute | 2 | 2024 | 68 | 0.520 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2018 | 90 | 0.510 |
Why?
| | Hypertension, Portal | 1 | 2017 | 66 | 0.480 |
Why?
| | Liver Neoplasms | 2 | 2022 | 777 | 0.460 |
Why?
| | Severity of Illness Index | 7 | 2022 | 2933 | 0.460 |
Why?
| | Adolescent | 17 | 2026 | 22577 | 0.450 |
Why?
| | Absorptiometry, Photon | 2 | 2026 | 277 | 0.430 |
Why?
| | Waiting Lists | 4 | 2021 | 266 | 0.420 |
Why?
| | Preoperative Care | 1 | 2017 | 380 | 0.410 |
Why?
| | Humans | 48 | 2026 | 145783 | 0.410 |
Why?
| | Body Mass Index | 5 | 2026 | 2447 | 0.400 |
Why?
| | Graft Survival | 6 | 2022 | 519 | 0.390 |
Why?
| | Oxidative Stress | 2 | 2018 | 1360 | 0.380 |
Why?
| | Infant | 13 | 2025 | 10091 | 0.360 |
Why?
| | Obesity | 4 | 2022 | 3118 | 0.350 |
Why?
| | Nutritional Status | 3 | 2025 | 353 | 0.350 |
Why?
| | Postoperative Complications | 4 | 2025 | 2977 | 0.340 |
Why?
| | Alanine Transaminase | 2 | 2025 | 151 | 0.300 |
Why?
| | Metabolic Syndrome | 2 | 2013 | 361 | 0.300 |
Why?
| | Metabolism, Inborn Errors | 1 | 2008 | 42 | 0.270 |
Why?
| | Biomarkers | 5 | 2024 | 4302 | 0.270 |
Why?
| | Fructose | 2 | 2022 | 132 | 0.270 |
Why?
| | Female | 23 | 2026 | 79045 | 0.260 |
Why?
| | F2-Isoprostanes | 2 | 2018 | 21 | 0.260 |
Why?
| | Eosinophilic Esophagitis | 2 | 2025 | 332 | 0.260 |
Why?
| | Infant Mortality | 1 | 2008 | 128 | 0.260 |
Why?
| | Male | 23 | 2026 | 73011 | 0.260 |
Why?
| | Portoenterostomy, Hepatic | 3 | 2022 | 43 | 0.260 |
Why?
| | Quality of Life | 3 | 2023 | 3211 | 0.250 |
Why?
| | Bile Acids and Salts | 1 | 2008 | 163 | 0.250 |
Why?
| | Living Donors | 4 | 2022 | 282 | 0.250 |
Why?
| | Child, Preschool | 14 | 2025 | 11868 | 0.240 |
Why?
| | Body Composition | 3 | 2026 | 693 | 0.240 |
Why?
| | Retrospective Studies | 15 | 2025 | 17330 | 0.240 |
Why?
| | Insulin Resistance | 3 | 2026 | 1244 | 0.240 |
Why?
| | Chronic Disease | 2 | 2025 | 1812 | 0.230 |
Why?
| | Treatment Outcome | 8 | 2025 | 11794 | 0.230 |
Why?
| | Alagille Syndrome | 2 | 2024 | 29 | 0.230 |
Why?
| | Cholestasis, Intrahepatic | 2 | 2023 | 29 | 0.230 |
Why?
| | Nutritional Support | 1 | 2025 | 39 | 0.220 |
Why?
| | alpha-Fetoproteins | 1 | 2024 | 42 | 0.210 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2024 | 42 | 0.200 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2025 | 317 | 0.190 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 58 | 0.190 |
Why?
| | Cross-Sectional Studies | 4 | 2025 | 5925 | 0.190 |
Why?
| | Elasticity Imaging Techniques | 1 | 2022 | 58 | 0.170 |
Why?
| | Survival Rate | 4 | 2017 | 2094 | 0.170 |
Why?
| | Hepatic Veins | 1 | 2021 | 32 | 0.170 |
Why?
| | Airway Extubation | 1 | 2022 | 60 | 0.170 |
Why?
| | Dietary Carbohydrates | 1 | 2022 | 147 | 0.170 |
Why?
| | Vaccination | 2 | 2020 | 1428 | 0.170 |
Why?
| | Immunosuppressive Agents | 2 | 2017 | 838 | 0.170 |
Why?
| | Abdominal Fat | 1 | 2021 | 51 | 0.170 |
Why?
| | Endoscopy, Digestive System | 2 | 2025 | 142 | 0.160 |
Why?
| | Vascular Malformations | 1 | 2021 | 52 | 0.160 |
Why?
| | Health Services Accessibility | 2 | 2021 | 1101 | 0.160 |
Why?
| | Infant, Newborn | 7 | 2024 | 6465 | 0.160 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2968 | 0.160 |
Why?
| | Portal Vein | 1 | 2021 | 117 | 0.160 |
Why?
| | Metabolic Diseases | 1 | 2021 | 114 | 0.160 |
Why?
| | Primary Graft Dysfunction | 1 | 2020 | 33 | 0.160 |
Why?
| | Cohort Studies | 5 | 2022 | 6033 | 0.160 |
Why?
| | gamma-Glutamyltransferase | 2 | 2011 | 42 | 0.150 |
Why?
| | Vaccines, Attenuated | 1 | 2020 | 129 | 0.150 |
Why?
| | Eating | 1 | 2022 | 387 | 0.150 |
Why?
| | Remission Induction | 1 | 2020 | 306 | 0.150 |
Why?
| | Enteral Nutrition | 1 | 2021 | 217 | 0.150 |
Why?
| | Transplant Recipients | 1 | 2020 | 182 | 0.140 |
Why?
| | Postoperative Care | 1 | 2020 | 286 | 0.140 |
Why?
| | Case-Control Studies | 1 | 2025 | 3634 | 0.130 |
Why?
| | Hepatitis, Autoimmune | 1 | 2017 | 14 | 0.130 |
Why?
| | Thioguanine | 1 | 2017 | 18 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1372 | 0.130 |
Why?
| | Aspartate Aminotransferases | 2 | 2022 | 85 | 0.130 |
Why?
| | Azathioprine | 1 | 2017 | 44 | 0.130 |
Why?
| | Emotional Adjustment | 1 | 2017 | 18 | 0.130 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2021 | 390 | 0.130 |
Why?
| | Glucose | 1 | 2022 | 1049 | 0.120 |
Why?
| | Anesthetics, Intravenous | 1 | 2017 | 69 | 0.120 |
Why?
| | Adiposity | 1 | 2021 | 532 | 0.120 |
Why?
| | Pediatrics | 2 | 2016 | 1125 | 0.120 |
Why?
| | Propofol | 1 | 2017 | 85 | 0.120 |
Why?
| | Tissue and Organ Procurement | 1 | 2020 | 343 | 0.120 |
Why?
| | Family Relations | 1 | 2017 | 88 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 900 | 0.120 |
Why?
| | Blood Glucose | 1 | 2026 | 2344 | 0.110 |
Why?
| | Aldehydes | 1 | 2016 | 140 | 0.110 |
Why?
| | Nicardipine | 1 | 2015 | 6 | 0.110 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 655 | 0.110 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2017 | 139 | 0.110 |
Why?
| | Prevalence | 3 | 2025 | 2875 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1150 | 0.110 |
Why?
| | Food Hypersensitivity | 1 | 2017 | 164 | 0.110 |
Why?
| | Healthcare Disparities | 1 | 2021 | 736 | 0.110 |
Why?
| | Communicable Diseases | 1 | 2017 | 166 | 0.100 |
Why?
| | Immunization | 1 | 2016 | 375 | 0.100 |
Why?
| | Tacrolimus | 1 | 2015 | 196 | 0.100 |
Why?
| | Gastroenterology | 1 | 2016 | 191 | 0.100 |
Why?
| | Hyperuricemia | 1 | 2013 | 47 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1547 | 0.100 |
Why?
| | Dietary Sucrose | 1 | 2013 | 50 | 0.100 |
Why?
| | Health Policy | 1 | 2017 | 400 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 1 | 2026 | 3916 | 0.100 |
Why?
| | Sweetening Agents | 1 | 2013 | 57 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5428 | 0.090 |
Why?
| | Uric Acid | 1 | 2013 | 167 | 0.090 |
Why?
| | Registries | 3 | 2022 | 2410 | 0.090 |
Why?
| | Pilot Projects | 1 | 2018 | 1898 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.090 |
Why?
| | Steroids | 1 | 2012 | 160 | 0.090 |
Why?
| | Hemochromatosis | 1 | 2011 | 9 | 0.090 |
Why?
| | Hyperbilirubinemia | 1 | 2011 | 11 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 25 | 0.080 |
Why?
| | International Normalized Ratio | 1 | 2011 | 55 | 0.080 |
Why?
| | Nutrition Surveys | 1 | 2012 | 279 | 0.080 |
Why?
| | Inflammation | 1 | 2022 | 2884 | 0.080 |
Why?
| | Parenteral Nutrition | 1 | 2012 | 102 | 0.080 |
Why?
| | Regression Analysis | 1 | 2013 | 1001 | 0.080 |
Why?
| | Herpes Simplex | 1 | 2011 | 99 | 0.080 |
Why?
| | Reoperation | 2 | 2015 | 637 | 0.080 |
Why?
| | Odds Ratio | 1 | 2012 | 1083 | 0.080 |
Why?
| | Length of Stay | 2 | 2022 | 1350 | 0.080 |
Why?
| | Models, Statistical | 1 | 2013 | 672 | 0.070 |
Why?
| | Pruritus | 1 | 2008 | 60 | 0.070 |
Why?
| | Prognosis | 3 | 2024 | 4330 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 614 | 0.070 |
Why?
| | Dietary Supplements | 1 | 2012 | 584 | 0.060 |
Why?
| | Logistic Models | 1 | 2012 | 2139 | 0.060 |
Why?
| | Antibiotic Prophylaxis | 1 | 2008 | 134 | 0.060 |
Why?
| | Hospitalization | 1 | 2017 | 2461 | 0.060 |
Why?
| | Energy Intake | 2 | 2023 | 512 | 0.060 |
Why?
| | Time Factors | 1 | 2017 | 7134 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 2123 | 0.060 |
Why?
| | Pregnancy | 3 | 2023 | 7216 | 0.060 |
Why?
| | United States | 5 | 2021 | 16126 | 0.050 |
Why?
| | Prospective Studies | 2 | 2021 | 8078 | 0.050 |
Why?
| | Comorbidity | 1 | 2009 | 1662 | 0.050 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 92 | 0.050 |
Why?
| | Sugars | 1 | 2023 | 40 | 0.050 |
Why?
| | Fibroblast Growth Factors | 1 | 2024 | 188 | 0.050 |
Why?
| | Plethysmography | 1 | 2022 | 104 | 0.050 |
Why?
| | Graft Rejection | 2 | 2017 | 521 | 0.050 |
Why?
| | Risk Factors | 2 | 2017 | 10919 | 0.050 |
Why?
| | ROC Curve | 1 | 2024 | 618 | 0.040 |
Why?
| | Anthropometry | 1 | 2022 | 206 | 0.040 |
Why?
| | Vaccines | 2 | 2017 | 389 | 0.040 |
Why?
| | Aged | 1 | 2022 | 26217 | 0.040 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2022 | 154 | 0.040 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2023 | 178 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2022 | 249 | 0.040 |
Why?
| | North America | 1 | 2022 | 304 | 0.040 |
Why?
| | Age Factors | 1 | 2008 | 3346 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 288 | 0.040 |
Why?
| | Risk Assessment | 2 | 2022 | 3752 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2022 | 360 | 0.040 |
Why?
| | Incidence | 2 | 2017 | 2934 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2022 | 223 | 0.040 |
Why?
| | Triglycerides | 1 | 2022 | 520 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 517 | 0.040 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2013 | 2602 | 0.040 |
Why?
| | Fatigue | 1 | 2021 | 366 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2017 | 42 | 0.030 |
Why?
| | Contraindications, Drug | 1 | 2017 | 10 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2022 | 714 | 0.030 |
Why?
| | Transplantation Immunology | 1 | 2017 | 29 | 0.030 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 88 | 0.030 |
Why?
| | Diet Therapy | 1 | 2017 | 36 | 0.030 |
Why?
| | Palivizumab | 1 | 2016 | 11 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 65 | 0.030 |
Why?
| | Young Adult | 1 | 2013 | 14254 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 428 | 0.030 |
Why?
| | Liver Failure | 1 | 2016 | 83 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2017 | 202 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1278 | 0.030 |
Why?
| | Canada | 1 | 2016 | 432 | 0.030 |
Why?
| | Immunization Programs | 1 | 2016 | 193 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2015 | 162 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1271 | 0.020 |
Why?
| | Drug Interactions | 1 | 2015 | 405 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 782 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 740 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2017 | 475 | 0.020 |
Why?
| | Skinfold Thickness | 1 | 2012 | 43 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2015 | 401 | 0.020 |
Why?
| | Animals | 2 | 2013 | 38102 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2015 | 521 | 0.020 |
Why?
| | Adult | 1 | 2013 | 40881 | 0.020 |
Why?
| | Weight Gain | 1 | 2013 | 561 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1582 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2013 | 692 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4556 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 668 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2016 | 6085 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4568 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 2191 | 0.010 |
Why?
|
|
Sundaram's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|